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Background: APVT is an invasive method recommended for symptomatic patients with PAH
that permits the identification of the minority of patients (<20%) that may benefit from
long-term calcium channel blockers. Adenosine has been indicated in guidelines as a vasodi-
lator agent of choice for APVT, although it has not been directly compared with iNO, the gold
standard for this test. The objective of the study was to compare adenosine with inhaled nitric
oxide (iNO) for acute pulmonary vasoreactivity testing (APVT) in pulmonary arterial hyperten-
sion (PAH), in order to determine the efficacy and safety of the first in the clinical setting.
Methods: The measurements of cardiac output, pulmonary and systemic resistance were done
in the basal state and with a stepwise increase of the dose of each drug until either maximum
dosage (adenosine: 500 mg/kg/min or iNO: 80 ppm) or side effects observed or a positive
response were reached, according to current guidelines. The order of drugs used in each test
was consecutively alternated during the study.
Results: Six of the 39 studied patients (15%) presented a positive response to iNO; none to
adenosine (p Z 0.047, McNemar’s test). Twenty-three patients (59%) did not reach the
maximum dose of adenosine due to side effects, including bronchospasm, thoracic pain and
bradycardia.y vasoreactivity testing; CCB, Calcium channel blocker; CHD, Congenital heart disease; CO, Cardiac
A, Pulmonary artery; PAH, Pulmonary arterial hypertension; PCWP, Pulmonary capillary wedged
sistance; WHO, World Health Organization.
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Vasoreactivity testing in pulmonary hypertension 607Conclusions: APVT testing with adenosine was not able to detect PAH patients responsive to
iNo and provoked frequent adverse effects. Adenosine should not be used as a vasodilator drug
in APVT.
ª 2009 Elsevier Ltd. All rights reserved.Introduction
Pulmonary arterial hypertension (PAH), defined by a mean
pulmonary arterial pressure higher than 25 mmHg at rest or
30 mmHg during exercise, is a group of diseases charac-
terized by a progressive increase of pulmonary vascular
resistance (PVR) leading to right ventricular failure and
premature death.1 PAH is classified, according to the
etiology, as idiopathic, when the cause is unknown, or
secondary, when the cause is known, as connective tissue
disease, congenital heart disease (CHD), portal hyperten-
sion, or chronic thrombotic and/or embolic disease.2 In the
last 20 years, diagnostic and treatment options for patients
with the disease have evolved to help in prolonging their
survival and improving their quality of life.
Treatment with high doses of calcium channel blockers
(CCBs) has been shown to have a sustained beneficial effect
in a small subset of patients with symptomatic idiopathic
PAH who demonstrated an acute fall in pulmonary artery
pressure in response to a pulmonary vasodilator.3e5 The
empirical use of CCBs is discouraged because of the risks of
systemic hypotension and impaired right-sided heart func-
tion.6 Consequently, the current recommendations for the
treatment of PAH propose that the acute response of the
pulmonary circulation to a pulmonary vasodilator should be
used as the basis for selecting patients for high-dose CCB
treatment.1,7,8 Current guidelines recommend acute
pulmonary vasoreactivity testing (APVT) for all symptom-
atic patients with idiopathic PAH and, presumably, for most
cases of secondary disease.1,7,8 However, this is an invasive
procedure, which involves a small but definite risk of
complications and death.9
According to these guidelines,1,7,8 APVT should be per-
formed using short-acting pulmonary vasodilators, such as
intravenous prostacyclin or adenosine and inhaled nitric
oxide (iNO). The use of adenosine is particularly attractive,
since it is easily available and has short half-life and low
cost.10 Nonetheless, there are few published reports about
the efficacy of adenosine as a vasodilator test in the clinical
setting and none of them evaluated the diagnostic perfor-
mance of the drug in comparison with iNO, the gold stan-
dard for the test.10e12
The aim of this study is to compare adenosine with iNO
for vasoreactivity testing in PAH, in order to determine the
efficacy and safety of the former in the clinical setting.Methods
Patients
The study sample consists of consecutive patients with PAH
referred to evaluate pulmonary vascular reactivity at the
Hospital das Clı´nicas da Universidade Federal de MinasGerais, Brazil, from January 2006 to December 2007.
Pregnancy and contra-indication to catheterization were
the exclusion criteria. The final sample included 39 patients
between 2 and 69 years-old, 82% of them being females.
Research protocol
The research protocol was approved by the institutional
ethics committee and all participants or their parents gave
written consent.
The APVT was conducted under mild sedation in 36 of
the 39 patients, and under general anesthesia in the other
3. The pressures were measured in pulmonary artery (PA),
right atrium, aorta and in the left atrium, in the presence of
patent foramen ovale. In the absence of patent foramen
ovale, left atrium pressure was obtained by the pulmonary
capillary wedged pressure (PCWP) measured by the Swan-
Ganz catheter. The cardiac output (CO) was calculated by
the Fick method, with an estimation of oxygen consump-
tion. The pulmonary vascular resistance was calculated as
(mean PA pressure e PCWP)/CO. The systemic vascular
resistance was calculated as (mean systemic blood pressure
e right atrial pressure)/CO. The systemic arterial pressure
was monitored by the insertion of a catheter in the femoral
artery. Independently of the stage of the test, the
measurements were carried out only with the pH within the
normal limits, PCO2 below 45 mmHg, body temperature
between 36 and 37,5 C and systemic pressure within a 10%
difference of the normal values for each patient. Nitric
oxide was administered by facial mask in 36 patients and by
endotracheal tube in 3 patients and adenosine into the
pulmonary artery by continuous administration.
All measurements, including cardiac output and pulmo-
nary and systemic resistance assessment, were done in the
basal state and with a stepwise increase of the dose of each
drug, starting with 10 ppm of iNO or 50 mg/kg/min of
adenosine, followed by increases every 5 min until either
maximum dosage (adenosine: 500 mg/kg/min or iNO:
80 ppm) or a positive response were reached or side effects
observed.1,7 The test with the second drug was performed
only after the measurements returned to the basal values.
The order of drugs used in each test was consecutively
alternated during the study. A positive response was
defined as a reduction of mean pulmonary artery pressure
10 mmHg to reach an absolute value of 40 mmHg, with
an increased or unchanged cardiac output1,7,8; in the PAH
secondary to CHD, as an increase in the pulmonary flow/
systemic flow ratio >1.8, associated with a reduction in
pulmonary resistance/systemic resistance ratio >30%.13,14
Statistical methods
Data obtained from continuous variables are expressed as
mean  standard deviation or median with the interquartile
608 E.C. Oliveira et al.range. Comparison between measurements at maximal
dose versus basal state during each vasodilator challenge
and between challenges was performed using student t test
for paired samples. Data concerning categorical variables
are expressed as proportions and were compared by
McNemar test for paired samples. A p value of <.05 was
considered significant.
The sample size was calculated using the software Study
Size v. 2.0.2 (Va¨stra Fro¨lunda, Sweden) after a pilot study
of 20 patients, without any positive response to adenosine.
Considering paired observations, alpha value of 0.05, beta
values of 0.8, and 2% of response to adenosine and 20% to
iNO, a sample size of 39 patients was obtained.
Results
General features
The study sample consisted of 39 patients (32 females) with
a mean age of 40 (SD Z 16), median weight of 60 kg
(interquartile rangeZ 48e67). Most patients had idiopathic
HAP (26 cases), and specific etiologies included colagenosis
(4), Schistosomiasis (4), CHD (3) and pulmonary thrombo-
embolism (2). The majority of patients were in World
Health Organization (WHO) class IV (18/46, 46%); 13 (33%)
in WHO class III and only eight (21%) in class II.
Response to acute pulmonary vasoreactivity testing
Six of the 39 patients studied (15%) presented a positive
response to iNO; none to adenosine (pZ 0.047, McNemar’s
test): four with idiopathic PAH, one with esclerodermia and
another with CHD. Twenty-three patients (59%) did not
reach the maximum dose of adenosine due to side effects,
including bronchospasm, thoracic pain and bradycardia
(see Table 1). Side effects were not observed during iNO
tests.
Table 2 shows hemodynamic measurements at basal
state and after maximum dose of adenosine or iNO. iNOTable 1 Response to acute pulmonary vasoreactivity
testing in 39 patients with pulmonary artery hypertension.
Inhaled nitric oxide challenge
Maximum dosage, nitric oxide, ppm* 80 (80e80)
Positive response to nitric oxide challenge 6 (15)
Side effects to nitric oxide challenge 0 (0)
Intravenous adenosine challenge
Maximum dosage, adenosine, mg/kg/min* 200 (150e500)
Positive response to adenosine challenge 0 (0)
Side effects to adenosine challenge 23 (60)
Broncospasm 15 (38)
Thoracic pain 11 (28)
Bradycardia 5 (13)
Data expressed as absolute number (proportion), except
*median (interquartile range). Adenosine pharmacological
activity was confirmed by the successful treatment of supra-
ventricular tachycardia by vials of the same lot used in this
study.produced a decrease of mean heart rate and of mean
pulmonary arterial pressures, mean and systolic, and
pulmonary resistance index; all other measurements and
indexes were unaltered. Adenosine did not produce any
significant modification of measured pressures and indexes.
A post-hoc analysis was performed using only patients
with idiopathic PAH (n Z 26) and in adults (>17 years,
n Z 36). In both situations, no significant differences from
data displayed in Table 2 were observed. A positive
response to the AVPTwith iNO was observed in four patients
with idiopathic PAH (15%) and in five adults (14%); none
responded to adenosine (p Z 0.13 and p Z 0.065,
respectively, McNemar’s test).
Discussion
Acute pulmonary vasoreactivity testing and
pulmonary artery hypertension
APVT is pivotal in the evaluation of any patient with idio-
pathic PAH.1,8 The rationale for vasodilator testing in the
diagnostic evaluation of idiopathic PAH patients is based on
2 factors: 1) acute vasodilator responsiveness identifies
patients with a better prognosis; and 2) responders are
more likely to have a sustained beneficial response to oral
CCB than nonresponders and could be treated with these
less expensive drugs.8 However, only a small subset of
patients benefit from the chronic treatment with oral CCB.
In a landmark study, Sitbon et al.,5 using the definition of
a positive response as a 20% fall in both pulmonary artery
pressure and vascular resistance with either intravenous
epoprostenol or iNO, found that only 38 of the 70 acute
responders (6.8% of the total IPAH study population) dis-
played long-term improvement with calcium channel
blocker therapy. Although the benefit is restricted to few
patients, it is significant and sustainable: in the same study,
after 7.0  4.1 years, all but 1 long-term CCB responders
were alive in NYHA class I or II, with a sustained hemody-
namic improvement. In the group of patients who failed on
CCB, the 5-year survival rate was 48%.5
In other PAH groups, there is limited evidence of the
benefit of APVT15,16 and the long-term responsiveness to
oral CCB seems to be even more infrequent.8 According to
recommendations of a recently published consensus, the
decision to proceed with acute testing in such patients
should be individualized.8 In patients with CHD, APVT can
define if PAH is due to increased pulmonary flow, in which
surgery would be indicated, or to increased pulmonary
resistance, where surgery is not indicated.13,14
There are uncertainties regarding the choice of vasodi-
lator to be used in APVT.3 Although the drug of choice is
iNO,17e19 inhaled iloprost, intravenous prostacyclin or
adenosine are considered acceptable alternatives.8 Gho-
frani stressed that these agents have different mechanisms
of action and, as a consequence, their use as agents to
assess pulmonary vasoreactivity might not be interchange-
able.8 Indeed, some agents have virtually no effect on
cardiac output (ie, iNO), others increase cardiac output
directly (ie, prostanoids) or indirectly (ie, intravenous
adenosine via systemic vasodilation and reflex
tachycardia).
Table 2 Hemodynamic measurements at basal state and after maximum dose of adenosine or inhaled nitric oxide in 39
patients with pulmonary artery hypertension.
Nitric Oxide Adenosine Comparison
Basal Maximal dose p Basal Maximal dose p p
Heart rate 89.7  13.9 86.2  13.2 <0.001 87.4  13.0 88.3  16.5 0.592 0.024
PWP 9.6  3.2 9.9  3.0 0.302 9.7  3.3 9.7  3.6 0.809 0.460
Right atrial pressure 8.6  4.4 9.1  3.9 0.122 9.1  4.2 9.5  4.4 0.139 0.786
Cardiac index 3.1  0.9 3.4  1.5 0.069 3.1  0.9 3.0  0.9 0.096 0.038
Systemic AP, systolic 121.4  29.9 120.0  25.4 0.377 122.3  28.1 119.4  26.8 0.089 0.296
Systemic AP, mean 86.5  19.7 87.8  19.7 0.220 87.0  19.8 86.5  20.0 0.636 0.133
Systemic resistance
index
2130.3  684.1 2091.1  715.4 0.389 2140.1  704.8 2139.6  724.7 0.986 0.416
Pulmonary AP, systolic 95.3  27.1 91.1  27.1 0.008 94.6  26.1 96.5  26.4 0.141 0.001
Pulmonary AP, mean 61.0  17.2 58.0  18.7 0.003 61.1  17.1 61.5  16.2 0.543 0.001
Pulmonary resistance
index
1447.1  557.6 1319.1  669.3 0.002 1474.3  561.5 1489.8  595.5 0.695 0.006
Data are means standard deviation. p-values refer to comparison between measurements at maximal dose versus basal state during
each vasodilator challenge and between challenges (last column), always using paired student t test. All measurements expressed as
millimeters of mercury, except heart rate (beats per minute), cardiac index (l/min/m2) and resistance indexes (dynes.s.cm5/m2)
PWP Z pulmonary capillary wedge pressure; AP Z arterial pressure.
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especially in developing countries, the low cost, widely
available adenosine seems to be a good option in the
performance of APVT. However, no head-to-head compar-
ison with standard iNO could be found in the literature.
Adenosine and acute pulmonary vasoreactivity
testing
Adenosine is universally used for the treatment of supra-
ventricular tachycardia, being considered the choice drug
for that indication.20 It is short-lived, similar to the nitric
oxide (less than 15 s), and its side effects, such as brady-
cardia, bronchospasm and precordial discomfort, disap-
pear quickly after its interruption.21 Several publications
report the utilization of the adenosine, with good results,
for the treatment of pulmonary hypertension of several
causes.22e27
Adenosine’s pulmonary vasodilating action arouses
interest in its use in pulmonary vasoreactivity tests.
However, few studies on the use of adenosine in clinical
APVT have been conducted.10e12 In 1991, Morgan et al.,10
studying seven patients with primary PAH, described a dose
dependent reduction (mean maximal percent decrease of
38.9% from baseline) of pulmonary vascular resistance in all
studied patients, associated with a increase of the cardiac
output. In this study, the mean decrease of the mean
pulmonary artery pressure was 8.3% at the maximal dose of
0.05 mg/kg/min, considering a mean value at the baseline
of 52.7 mmHg.10 In 1992, Schrader et al.12 studied 15
patients with PAH with both nifedipine and adenosine.
Adenosine was infused at 50 mg/kg/min, increased by
50 mg/kg/min at 2 min intervals to a maximum of 500 mg/
kg/min or until the development of untoward side effects.
The administration of maximal doses of adenosine,
256  46 mg/kg/min, produced a 2.4% reduction in
pulmonary artery pressure (p Z NS), a 37% decrease in
pulmonary vascular resistance (p < 0.001) and a 57%increase in cardiac index (p < 0.001). Finally, Nootens
et al.,11 in 1995, compared the acute hemodynamic effects
of adenosine and prostacyclin in ten patients with severe
primary pulmonary hypertension, unresponsive to medical
therapy. After baseline hemodynamics were obtained, an
adenosine infusion, 50e100 ng/kg/min, was begun and
titrated to the maximum tolerated dose. Overall, adeno-
sine (200  53 ng/kg/min) produced a 33  18% (p < 0.001)
fall in pulmonary vascular resistance and a 52  25%
(p < 0.001) increase in cardiac output with no effect on
pulmonary or systemic arterial pressures. The hemody-
namic effects were considered similar to that obtained
with prostacyclin infusion (2 ng/kg/min titrated to the
maximum tolerated dose).
Implications of our results
To our knowledge, our study is the first head-to-head
comparison of adenosine and iNO, using standardized
methodology for APVT. In this sample, adenosine did not
perform well as a vasodilating agent in APVT: significant
side effects occurred in 23 (60%) of the patients and none of
those responsive to iNO had a significant response to
adenosine (Table 1). Moreover, adenosine did not produce
any major reduction of pulmonary artery pressure or
vascular resistance (Table 2). Since adenosine failed to
reproduce the pulmonary artery vasodilator effect of iNO,
it would have also failed to recognize six out of 39 candi-
dates to long-term treatment with CCB. In short, adenosine
does not seem to be useful as a vasodilator agent in APVT.
Indeed, adenosine has been introduced in clinical prac-
tice as a vasodilator agent in APVT after very limited
reported experience: only 32 patients have been submitted
to acute vasoreactivity test with adenosine in those articles
cited above. In those studies, the reduction of the pulmo-
nary artery pressure was absent11,12 or was less than
10 mmHg,10 the established value for significant vasodilator
response in the APVT.1,7,8 Thus, there is no proof that
610 E.C. Oliveira et al.adenosine acute challenge can elicit a vasoreactivity
response similar to that observed with iNO, with significant
reduction of PA pressure. Moreover, none of the studies in
which the long-term benefit of the treatment with CCB was
demonstrated used the adenosine test in the selection of
responsive patients.4e6,18
Thus, adenosine was included as a vasodilator agent of
choice in current guidelines and consensus with a very low
level of evidence. The scarcity of data regarding PAH,
a relatively rare disease, could have justified this situation.
However, it does not seem to be an exception: in a recent
study, Tricoci et al. showed that recommendations from
current established guidelines are frequently not supported
by robust evidence.28
Limitations
The study has several limitations. Since we did not follow
the iNO-responsive patients to confirm that they would
benefit from long-term CCB therapy, we could not evaluate
the superiority of iNO over adenosine as a vasodilator agent
in APVT. We studied both idiopathic and secondary forms of
PAH, although the test is an established method only in the
former. However, a separate analysis of idiopathic PAH
patients showed similar results. The patients included
comprise a very wide spectrum of age (range 2e69 years)
and children may behave differently during the APVT.
However, when the analysis is restricted to adults, the
results were unchanged. The study sample (39 patients) is
not large, although the sample size was calculated in
advance. Since PAH is a relatively rare disease, our study
included more patients than the sum of all patients
selected in previous studies. Finally, the absence of
significant hemodynamic effects of adenosine could have
raised the suspicion of inactivity of the drug used in these
tests. This hypothesis was excluded, since typical adverse
effects were frequent in this sample and adenosine phar-
macological activity was confirmed by the successful
treatment of supraventricular tachycardia by vials of the
same lot used in this study.
Conclusion
APVT testing with adenosine was not able to detect PAH
patients responsive to iNo and provoked frequent adverse
effects. Considering the importance of the vasoreactivity
testing in selecting the appropriate therapy in PAH, the high
cost of specific therapies and the risks of the invasive
method, we conclude that adenosine should not be used as
a vasodilator drug in pulmonary vasoreactivity testing.
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